Literature DB >> 20074414

Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis.

D Webster1, R Long, C Shandro, J Pettipas, J Leblanc, R Davidson, A Fanning.   

Abstract

SETTING: Alberta, Canada, 1990-2003.
OBJECTIVE: Monotherapy of active tuberculosis (TB) promotes drug resistance. Given the common practice of empiric fluoroquinolone (FQ) therapy for urinary tract infections (UTI) and frequent delayed diagnosis of renal TB, we assessed urine Mycobacterium tuberculosis isolates for FQ resistance.
DESIGN: Retrospective study. Urine M. tuberculosis isolates underwent FQ susceptibility testing. Records were reviewed for evidence of FQ exposure and diagnostic delay.
RESULTS: Among 78 culture-positive renal TB patients between 1990 and 2003, initial isolates of M. tuberculosis were available from 74 (94.9%). Three (4.1%) were FQ-resistant. Previous FQ use was confirmed in nine cases (12.2%). FQ-exposed isolates were more likely than non-exposed isolates to be FQ-resistant (2/9, 22.2% vs. 1/65, 1.5%, P = 0.037). Among 41 cases (55.4%) with signs or symptoms of UTI, eight (19.5%) had previous FQ exposure, of which seven (87.5%) had delayed diagnosis. Only 15/33 (45.5%) UTI symptomatic cases without prior FQ exposure had delayed diagnosis (P = 0.050). In 2/8 (25%) UTI symptomatic cases with prior FQ exposure, the M. tuberculosis isolate was FQ-resistant.
CONCLUSION: FQ monotherapy of unsuspected renal TB may delay diagnosis and lead to FQ resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20074414

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  A 68-year-old woman with recurrent cystitis.

Authors:  Monica Mutyala; Ruba A Halloush; Faisal A Khasawneh
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Mar-Apr       Impact factor: 2.471

2.  Renal tuberculosis tends to be low symptoms: how to improve the diagnosis and treatment of renal tuberculosis.

Authors:  Jing Wang; Song Fan; Jun Xiao; Chao-Zhao Liang
Journal:  Asian J Androl       Date:  2016 Jan-Feb       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.